OPKO’s Longer-Acting Clotting Factor VIIa-CTP Receives Orphan Drug Designation in the U.S.

[Business Wire] – OPKO Health, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation to OPKO’s longer-acting version of clotting Factor VIIa for the treatment of bleeding episodes in patients with hemophilia more

View todays social media effects on OPK

View the latest stocks trending across Twitter. Click to view dashboard

See who OPKO is hiring next, click here to view